Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

Hasina Samji, Angela Cescon, Robert S Hogg, Sharada P Modur, Keri N Althoff, Kate Buchacz, Ann N Burchell, Mardge Cohen, Kelly A Gebo, M John Gill, Amy Justice, Gregory Kirk, Marina B Klein, P Todd Korthuis, Jeff Martin, Sonia Napravnik, Sean B Rourke, Timothy R Sterling, Michael J Silverberg, Stephen Deeks, Lisa P Jacobson, Ronald J Bosch, Mari M Kitahata, James J Goedert, Richard Moore, Stephen J Gange, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, Hasina Samji, Angela Cescon, Robert S Hogg, Sharada P Modur, Keri N Althoff, Kate Buchacz, Ann N Burchell, Mardge Cohen, Kelly A Gebo, M John Gill, Amy Justice, Gregory Kirk, Marina B Klein, P Todd Korthuis, Jeff Martin, Sonia Napravnik, Sean B Rourke, Timothy R Sterling, Michael J Silverberg, Stephen Deeks, Lisa P Jacobson, Ronald J Bosch, Mari M Kitahata, James J Goedert, Richard Moore, Stephen J Gange, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

Abstract

Background: Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000-2007 in the U.S. and Canada.

Methods: Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.

Results: The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000-2002 to 2006-2007. Men and women had comparable life expectancies in all periods except the last (2006-2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm(3).

Conclusions: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Age-specific unweighted mortality rates (per…
Figure 1. Age-specific unweighted mortality rates (per 1000 person-years), by calendar-period, among individuals on ART in the NA-ACCORD, 2000–2007.
Note: PY, person-years; ART, combination antiretroviral therapy.
Figure 2. Mid-point life expectancy estimates at…
Figure 2. Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics, 2000–2007.
Panel A: Life expectancy at age 20 years, overall. Panel B: Life expectancy at age 20 years, by sex. Panel C: Life expectancy at age 20 years, by transmission group. Panel D: Life expectancy at age 20 years, by race. Panel E: Life expectancy at age 20 years, by CD4 cell count (cells/mm3) at ART initiation.

References

    1. Boyd MA (2009) Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 4: 194–199.
    1. ART Cohort Collaboration 2008 Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293.
    1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, et al. (2012) Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel. JAMA 308: 387–402.
    1. Wood E, Kerr T, Marshall BDL, Li K, Zhang R, et al. (2009) Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 338: b1649.
    1. Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532–539.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505.
    1. Justice AC (2010) HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 7: 69–76.
    1. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141–155.
    1. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155: 209–216.
    1. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, et al. (2009) Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49: 1570–1578.
    1. Palella FJ Jr, Baker RK, Buchacz K, Chmiel JS, Tedaldi EM, et al. (2011) Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25: 1865–1876.
    1. World Health Organization (2012) Life tables for WHO Member States. Available: . Accessed 18 December 2012.
    1. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, et al. (2007) Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 36: 294–301.
    1. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, et al. (2009) The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 50: 529–536.
    1. Chiang CL (1968) The life table and its construction. Introduction to Stochastic Processes in Biostatistics. New York: John Wiley and Sons. pp. 189–214.
    1. Bor J, Herbst AJ, Newell ML, Bärnighausen T (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961–5.
    1. World Health Organization (2013) Life Expectancy. Available: . Accessed: 30 September 2013.
    1. Miniño AM, Murphy SL, Xu J, Kochanek KD (2011) Deaths: Final Data for 2008. National Vital Statistics Reports 59.
    1. Robins JM, Finkelstein DM (2004) Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56: 779–788.
    1. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, et al. (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 148: 728–736.
    1. Marmot M (2005) Social determinants of health inequalities. Lancet 365: 1099–1104.
    1. Nakagawa F, May M, Phillips A (2013) Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26: 17–25.
    1. Wada N, Jacobson LP, Cohen M, French A, Phair J, et al. (2013) Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. Am J Epidemiol 177: 116–25.
    1. King JT, Justice AC, Roberts MS, Chang CCH, Fusco JS (2003) Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making 23: 9–20.
    1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, et al. (2007) Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21: 685–692.
    1. Simard EP, Fransua M, Naishadham D, Jemal A (2012) The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993–2007. Arch Intern Med 172: 1591–8.
    1. Lloyd-Smith E, Brodkin E, Wood E, Kerr T, Tyndall MW, et al. (2006) Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia. AIDS 20: 445–450.
    1. Wolfe D, Carrieri MP, Shepard D (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376: 355–366.
    1. Rubin MS, Colen CG, Link BG (2010) Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health 100: 1053–1059.
    1. DHHS: Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: . Accessed: 17 October 2012.
    1. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, et al. (2012) US trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 157: 325–335.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться